bg content top home

Smarter science.
Better health.

JULY 2016

RDD Pharma, an OrbiMed portfolio company, is a clinical stage therapeutics company. Our pipeline focuses on ano-rectal disorders, for which there is significant unmet need.

  • RDD Pharma presented their latest clinical research at Digestive Disease Week (DDW) in San Diego, CA on May 24, 2016. The presentation was entitled “The Effect of a Topical Alpha-Agonist on Fecal Incontinence in Spinal Cord Injury Patients.” Nir Barak, MD, RDD’s Chief Medical Officer, presented Phase 2a safety and efficacy data on RDD 0315 and its effect on
    fecal incontinence episodes in Spinal Cord Injury patients. The fecal incontinence market has the potential to approach
    $3B in sales.
  • RDD Pharma recently dosed its first patients in a multi-center, European Phase 3 study in Chronic Anal Fissure.
Target-icon

Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.

VISIT OUR TARGET PAGE

Strategey-icon

Safer investment and faster to market by leveraging New Therapeutic Entities (NTEs) based on approved molecules with established safety and toxicity profiles.

VISIT OUR STRATEGY PAGE

Pipeline-icon

Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).

VISIT OUR PIPELINE PAGE

video

Capository™ is our proprietary and licensable delivery system for precise delivery of molecules that target conditions/diseases of the anorectal region.

WATCH OUR VIDEO

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2016, RDD Pharma, Ltd. All rights reserved.

 

Menu
Go to top